Publications

  • Bergstrand, M., Söderlind, E., Eriksson, U., Weitschies, W., Karlsson, M. (2012). A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations. Pharmaceutical research, Springer Science+Business Media B.V.. vol. 29, ss. 574-584 [doi:10.1007/s11095-011-0595-2] [More information]
  • Bergstrand, M., Söderlind, E., Eriksson, U., Weitschies, W., Karlsson, M. (2012). A Semi-mechanistic Modeling Strategy to Link In Vitro and In Vivo Drug Release for Modified Release Formulations. Pharmaceutical research, vol. 29, ss. 695-706 [doi:10.1007/s11095-011-0594-3] [More information]
  • Hansson, E., Friberg, L. (2012). The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. Cancer Chemotherapy and Pharmacology, vol. 69, ss. 881-890 [doi:10.1007/s00280-011-1769-7] [More information]
  • Hennig, S., Nyberg, J., Fanta, S., Backman, J., Hoppu, K. et al. (2012). Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin. Journal of clinical pharmacology, vol. 52, ss. 347-360 [doi:10.1177/0091270010397731] [More information]
  • Kågedal, M., Cselényi, Z., Nyberg, S., Jönsson, S., Raboisson, P. et al. (2012). Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteer. NeuroImage [doi:10.1016/j.neuroimage.2012.02.085] [More information]
  • Lacroix, B., Friberg, L., Karlsson, M. (2012). Evaluation of IPPSE, an alternative method for sequential population PKPD analysis. Journal of Pharmacokinetics and Pharmacodynamics, vol. 39, ss. 177-193 [doi:10.1007/s10928-012-9240-x] [More information]
  • Lindell, M., Simonsson, U., Raffalli-Mathieu, F., Lannerbro, A., Honkakoski, P. et al. (2012). Induction of Drug Metabolism by Artemisinin: in vivo and Mechanistic Evidence for the Involvement of Nuclear Receptor CAR. Biochemical Pharmacology [More information]
  • Lledó-García, R., Hennig, S., Nyberg, J., Hooker, A., Karlsson, M. (2012). Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index. Journal of clinical pharmacology, vol. 52, ss. 29-38 [doi:10.1177/0091270010390041] [More information]
  • Mohamed, A., Nielsen, E., Cars, O., Friberg, L. (2012). Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrobial Agents and Chemotherapy, vol. 56, ss. 179-188 [doi:10.1128/AAC.00694-11] [More information]
  • Nyberg, J., Höglund, R., Bergstrand, M., Karlsson, M., Hooker, A. (2012). Serial correlation in optimal design for nonlinear mixed effects models. Journal of Pharmacokinetics and Pharmacodynamics [doi:10.1007/s10928-012-9245-5] [More information]
  • Quartino, A., Friberg, L., Karlsson, M. (2012). A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Investigational new drugs, vol. 30, ss. 833-845 [doi:10.1007/s10637-010-9603-3] [More information]
  • Rapp-Kesek, D., Rosborg, H., Wilbrand, K., Nyberg, J., Hooker, A. et al. (2012). Nutritional supplementation in patients after coronary-bypass surgery for unstable angina pectoris. [More information]
  • Viljoen, M., Karlsson, M., Meyers, T., Gous, H., Dandara, C. et al. (2012). Influence of CYP2B6 516G > T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. European Journal of Clinical Pharmacology, vol. 68, ss. 339-347 [doi:10.1007/s00228-011-1148-7] [More information]
  • Välitalo, P., Kumpulainen, E., Manner, M., Kokki, M., Lehtonen, M. et al. (2012). Plasma and Cerebrospinal Fluid Pharmacokinetics of Naproxen in Children. Journal of clinical pharmacology [doi:10.1177/0091270011418658] [More information]
  • Zhang, C., Denti, P., Decloedt, E., Maartens, G., Karlsson, M. et al. (2012). Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. British Journal of Clinical Pharmacology, vol. 73, ss. 758-767 [doi:10.1111/j.1365-2125.2011.04154.x] [More information]
  • Baverel, P., Savic, R., Karlsson, M. (2011). Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. Journal of Pharmacokinetics and Pharmacodynamics, vol. 38, ss. 63-82 [doi:10.1007/s10928-010-9177-x] [More information]
  • Bergstrand, M., Hooker, A., Wallin, J., Karlsson, M. (2011). Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models. AAPS Journal, vol. 13, ss. 143-151 [doi:10.1208/s12248-011-9255-z] [More information]
  • Bizzotto, R., Zamuner, S., Mezzalana, E., De Nicolao, G., Gomeni, R. et al. (2011). Multinomial Logistic Functions in Markov Chain Models of Sleep Architecture: Internal and External Validation and Covariate Analysis. AAPS Journal, vol. 13, ss. 445-463 [doi:10.1208/s12248-011-9287-4] [More information]
  • Gennemark, P., Danis, A., Nyberg, J., Hooker, A., Tucker, W. (2011). Optimal Design in Population Kinetic Experiments by Set-Valued Methods. AAPS Journal, vol. 13, ss. 495-507 [doi:10.1208/s12248-011-9291-8] [More information]
  • Jauslin, P., Frey, N., Karlsson, M. (2011). Modeling of 24-Hour Glucose and Insulin Profiles of Patients With Type 2 Diabetes. Journal of clinical pharmacology, vol. 51, ss. 153-164 [doi:10.1177/0091270010362536] [More information]
  • Johansson, Å., Hill, N., Perisoglou, M., Whelan, J., Karlsson, M. et al. (2011). A Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis Scores in Osteosarcoma. Therapeutic Drug Monitoring, vol. 33, ss. 711-718 [doi:10.1097/FTD.0b013e31823615e1] [More information]
  • Karlsson, K., Plan, E., Karlsson, M. (2011). Performance of three estimation methods in repeated time-to-event modeling. AAPS Journal, vol. 13, ss. 83-91 [doi:10.1208/s12248-010-9248-3] [More information]
  • Khandelwal, A., Harling, K., Jonsson, N., Hooker, A., Karlsson, M. (2011). A Fast Method for Testing Covariates in Population PK/PD Models. AAPS Journal, vol. 13, ss. 464-472 [doi:10.1208/s12248-011-9289-2] [More information]
  • Kjellsson, M., Ouellet, D., Corrigan, B., Karlsson, M. (2011). Modeling sleep data for a new drug in development using Markov mixed-effects models. Pharmaceutical research, vol. 28, ss. 2610-2627 [doi:10.1007/s11095-011-0490-x] [More information]
  • Nielsen, E., Cars, O., Friberg, L. (2011). Pharmacokinetic/Pharmacodynamic (PK/PD) indices of antibiotics predicted by a semi-mechanistic PKPD model: a step toward model-based dose optimization. Antimicrobial Agents and Chemotherapy, vol. 55, ss. 4619-4630 [doi:10.1128/AAC.00182-11] [More information]
  • Nielsen, E., Cars, O., Friberg, L. (2011). Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model. Antimicrobial Agents and Chemotherapy, vol. 55, ss. 1571-1579 [doi:10.1128/AAC.01286-10] [More information]
  • Nyberg, J., Ueckert, S., Strömberg, E., Hennig, S., Karlsson, M. et al. (2011). PopED: an extended, parallelized, population optimal design tool. Computer Methods and Programs in Biomedicine [More information]
  • Plan, E., Ma, G., Någård, M., Jensen, J., Karlsson, M. (2011). Transient Lower Esophageal Sphincter Relaxations PKPD Modeling: Count Model and Repeated Time-To-Event Model. Journal of Pharmacology and Experimental Therapeutics [doi:10.1124/jpet.111.181636] [More information]
  • Röshammar, D., Simonsson, U., Ekvall, H., Flamholc, L., Ormaasen, V. et al. (2011). Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.. Journal of Pharmacokinetics and Pharmacodynamics, vol. 38, ss. 727-742 [doi:10.1007/s10928-011-9217-1] [More information]
  • Sjögren, E., Nyberg, J., Magnusson, M., Lennernäs, H., Hooker, A. et al. (2011). Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment. Drug Metabolism And Disposition, vol. 39, ss. 858-863 [doi:10.1124/dmd.110.037309] [More information]
  • Trame, M., Bergstrand, M., Karlsson, M., Boos, J., Hempel, G. (2011). Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.. Clinical Cancer Research, vol. 17, ss. 6867-6877 [doi:10.1158/1078-0432.CCR-11-0074] [More information]
  • Wallin, J., Bergstrand, M., Wilczek, H., Nydert, P., Karlsson, M. et al. (2011). Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Therapeutic Drug Monitoring, vol. 33, ss. 663-672 [doi:10.1097/FTD.0b013e31823415cc] [More information]
  • Westin, J., Nyholm, D., Pålhagen, S., Willows, T., Groth, T. et al. (2011). A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. Clinical neuropharmacology, vol. 34, ss. 61-65 [doi:10.1097/WNF.0b013e31820b570a] [More information]
  • Bizzotto, R., Zamuner, S., De Nicolao, G., Karlsson, M., Gomeni, R. (2010). Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients. Journal of Pharmacokinetics and Pharmacodynamics, vol. 37, ss. 137-155 [doi:10.1007/s10928-009-9148-2] [More information]
  • Björnsson, M., Norberg, A., Kalman, S., Karlsson, M., Simonsson, U. (2010). A two-compartment effect site model describes the bispectral index after different rates of propofol infusion. Journal of Pharmacokinetics and Pharmacodynamics, vol. 37, ss. 243-255 [doi:10.1007/s10928-010-9157-1] [More information]
  • Elsherbiny, D., Ren, Y., McIlleron, H., Maartens, G., Simonsson, U. (2010). Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. European Journal of Clinical Pharmacology, vol. 66, ss. 1017-1023 [doi:10.1007/s00228-010-0847-9] [More information]
  • Ernest, C., Hooker, A., Karlsson, M. (2010). Methodological Comparison of In Vitro Binding Parameter Estimation: Sequential vs. Simultaneous Non-linear Regression. Pharmaceutical research, vol. 27, ss. 866-877 [doi:10.1007/s11095-010-0082-1] [More information]
  • Fanta, S., Jönsson, S., Karlsson, M., Niemi, M., Holmberg, C. et al. (2010). Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect of NR1I2 Polymorphism. Journal of clinical pharmacology, vol. 50, ss. 581-597 [doi:10.1177/0091270009348223] [More information]
  • Gupta, P., Friberg, L., Karlsson, M., Krishnaswami, S., French, J. (2010). A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis. Journal of clinical pharmacology, vol. 50, ss. 679-687 [doi:10.1177/0091270009346060] [More information]
  • Hansson, E., Wallin, J., Lindman, H., Sandström, M., Karlsson, M. et al. (2010). Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemotherapy and Pharmacology, vol. 65, ss. 839-848 [doi:10.1007/s00280-009-1089-3] [Free fulltext] [More information]
  • Karlsson, K., Wilkins, J., Jonsson, F., Zingmark, P., Karlsson, M. et al. (2010). Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales. AAPS Journal, vol. 12, ss. 683-691 [doi:10.1208/s12248-010-9230-0] [More information]
  • Keizer, R., Gupta, A., Mac Gillavry, M., Jansen, M., Wanders, J. et al. (2010). A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. Journal of Pharmacokinetics and Pharmacodynamics, vol. 37, ss. 347-363 [doi:10.1007/s10928-010-9164-2] [More information]
  • Kumpulainen, E., Valitalo, P., Kokki, M., Lehtonen, M., Hooker, A. et al. (2010). Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. British Journal of Clinical Pharmacology, vol. 70, ss. 557-566 [doi:10.1111/j.1365-2125.2010.03720.x] [More information]
  • Ma, G., Friberg, L., Movin-Osswald, G., Karlsson, M. (2010). Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin. British Journal of Clinical Pharmacology, vol. 70, ss. 815-824 [doi:10.1111/j.1365-2125.2010.03758.x] [More information]
  • Maloney, A., Schaddelee, M., Freijer, J., Krauwinkel, W., van Gelderen, M. et al. (2010). An example of optimal phase II design for exposure response modelling. Journal of Pharmacokinetics and Pharmacodynamics, vol. 37, ss. 475-491 [doi:10.1007/s10928-010-9168-y] [More information]
  • Petersson, K., Friberg, L., Karlsson, M. (2010). Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics, vol. 37, ss. 493-506 [doi:10.1007/s10928-010-9169-x] [More information]
  • Plan, E., Karlsson, K., Karlsson, M. (2010). Approaches to simultaneous analysis of frequency and severity of symptoms.. Clinical Pharmacology and Therapeutics, vol. 88, ss. 255-259 [doi:10.1038/clpt.2010.118] [More information]
  • Ribbing, J., Hamrén, B., Svensson, M., Karlsson, M. (2010). A Model for Glucose, Insulin, and Beta-Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes. Journal of clinical pharmacology, vol. 50, ss. 861-872 [doi:10.1177/0091270009349711] [More information]
  • Silber, H., Frey, N., Karlsson, M. (2010). An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers. Journal of clinical pharmacology, vol. 50, ss. 246-256 [doi:10.1177/0091270009341185] [Free fulltext] [More information]
  • Steimer, J., Dahl, S., De Alwis, D., Gundert-Remy, U., Karlsson, M. et al. (2010). Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics. European Journal of Cancer, vol. 46, ss. 21-32 [doi:10.1016/j.ejca.2009.10.011] [More information]